Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. It operates under the Beyond Air and Beyond Cancer segments. The firm developed the LungFit platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders. The company was founded in 2011 and is headquartered in Garden City, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

XAIR reports successful Q1 launch of LungFit PH, faces revenue challenges

XAIR's Q1 2023 performance reflects initial investment in commercial launch and R&D, with a focus on sustainable growth. The company's successful commercial launch of LungFit PH and plans for expansion demonstrate market potential. However, managing revenue expectations and strategic resource allocation present challenges. Anticipated international market expansion and the potential impact of the autism program offer future opportunities.

Beyond Air reports Q2 earnings, anticipates regulatory progress and challenges

Beyond Air's Q2 earnings call highlighted the commercial progress of LungFit PH, financial results, and strategic plans. The company faces challenges with reimbursement and contract signings but sees opportunities in VCAP trials and regulatory discussions.

XAIR anticipates strong revenue growth and market expansion opportunities

Beyond Air Inc's Q3 2023 performance reflected increased expenses and a GAAP net loss, with a focus on product development and market expansion.
Strengths include positive feedback on LungFit PH, strong leadership, and a dedicated commercial team driving successful launches.
Challenges include regulatory delays, hospital contracting issues, and delays in patient studies, requiring strategic resolutions.
Opportunities lie in team expansion, addressing contracting challenges, FDA meetings, and providing guidance for future growth.
headline

Beyond Air Inc reports successful product launch and secures funding

Beyond Air Inc's Q4 2023 earnings call highlighted a successful commercial launch of LungFit PH and debt financing to support growth initiatives.
While facing challenges such as $0 revenue and cash usage, the company aims to optimize operations and drive revenue generation.
Opportunities lie in expanding product offerings, enhancing customer service, and leveraging unique programs like the early-stage autism initiative.
Overall, Beyond Air Inc remains focused on driving commercial success and maintaining a strong market position through strategic initiatives.

Beyond Air Inc reports Q1 revenue growth and strategic financing

Beyond Air Inc's Q1 2024 earnings call highlighted revenue generation, increased expenses, and strategic financing. The company faces challenges in study endpoints and FDA agreements but sees opportunities in product expansions and regulatory approvals.

Beyond Air Inc reports Q2 earnings, eyes growth opportunities

Beyond Air Inc's Q2 2024 earnings call highlighted revenue guidance for FY 2025, strategic partnerships, and progress in research and development across multiple therapeutic areas.
The company's commercial success with LungFit PH, FDA approvals, and ongoing studies demonstrate a commitment to innovation and market growth amidst financial challenges.
Challenges in financial performance, market dynamics, and competition underscore the need for continued strategic planning and operational efficiency to drive sustainable profitability.
With a diversified pipeline, upcoming data releases, and product enhancements, Beyond Air Inc is poised to capitalize on growth opportunities and strengthen its position in the market.

Beyond Air Inc reports revenue growth and regulatory milestones ahead

Beyond Air Inc shows promising revenue growth and market acceptance, supported by new contracts and product demand.
While facing financial losses and regulatory uncertainties, the company's focus on innovation and customer relationships positions it well for future success.
Anticipated FDA decisions, ongoing hospital starts, and strong leadership underpin the company's growth potential and strategic outlook.

Beyond Air Q4: Growth Amid Challenges, Revenue Down

Beyond Air Inc. concluded fiscal Q4 2024 with significant developments and challenges. While the company demonstrated strong product usage and customer retention, it faces hurdles in customer acquisition speed and legal issues. Financially, the substantial net loss and revised down revenue projections highlight areas needing attention.

Beyond Air Inc reports growth in hospital clients and global expansion

Beyond Air Inc's Q2 2025 earnings call highlighted significant achievements, including a surge in hospital clients, strategic partnerships for global expansion, and progress on regulatory approvals for key products. The company showcased a commitment to financial sustainability through cash runway extension and cost reduction measures.
While facing challenges such as regulatory approval delays and a reported net loss, Beyond Air Inc remains focused on innovation and market growth. Opportunities lie in leveraging partnerships, product expansions, and cash reserves to drive future revenue and profitability.
Overall, Beyond Air Inc's performance reflects a mix of strengths, challenges, and opportunities, positioning the company for potential growth and market success. Analyst inquiries during the call underscored a keen interest in contract growth, strategic partnerships, and revenue prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

GARDEN CITY, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will present a corporate overview and participate in one-on-one meetings at BTIG's Virtual Biotechnology Conference, on Monday, August 7, 2023.

Beyond Air® To Participate in BTIG's 2023 Virtual Biotechnology Conference

Brainstorm Cell Therapeutics

Cosmos Holdings

Protagonist Therapeutics

Sharecare

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.

Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Today, we take a look at an interesting small-cap medical device concern called Beyond Air, Inc. The company is just rolling out its first approved product and has other assets in development. However, the company's balance sheet could be a concern.

Beyond Air: Dilution Remains A Concern

Beyond Air, Inc. (NASDAQ:XAIR ) Q4 2023 Earnings Conference Call June 22, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Year ended March 31, 2023. At this time, participants are in a listen-only mode.

Beyond Air, Inc. (XAIR) Q4 2023 Earnings Call Transcript

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.26 per share a year ago.

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Lags Revenue Estimates

Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023

Funding to support the commercialization of LungFit® PH and advance the clinical development of high concentration nitric oxide treatment using Beyond Air's revolutionary LungFit platform technology Funding to support the commercialization of LungFit® PH and advance the clinical development of high concentration nitric oxide treatment using Beyond Air's revolutionary LungFit platform technology

Beyond Air® Secures up to $40 Million Debt Financing

GARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd.

Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting

Air Transport Services Group

Newtek Business Services

Charles Schwab

Valley National

According to the Insider Cluster Buys Screen, a Premium feature of GuruFocus, five stocks that have high number of unique insider buys over the past three months are Air Transport Services Group Inc. ( ATSG , Financial), Beyond Air Inc. ( XAIR , Financial), Charles Schwab Corp. ( SCHW , Financial), Valley National Bancorp ( VLY , Financial) and NewtekOne Inc. ( NEWT , Financial).

5 Stocks Insiders Have Built Positions in Over the Past 3 Months

Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approval Dr. Myers brings extensive executive experience leading the development of clinical programs through US and global regulatory approval

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

Proffered abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM EDT Proffered abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting were released publicly today at 4:30 PM EDT

Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting

GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in two upcoming investor conferences in March 2023.

Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023

Beyond Air, Inc. (NASDAQ:XAIR ) Q3 2023 Earnings Conference Call February 9, 2023 4:30 PM ET Company Participants Edward Barger - Head, Investor Relations Steve Lisi - Chairman and CEO Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann Greg Fraser - Truist Securities Yale Jen - Laidlaw & Company Suraj Kalia - Oppenheimer & Company Operator Good afternoon. And welcome everyone to the Beyond Air Financial Results Call for the Third Fiscal Quarter ended December 31, 2022.

Beyond Air, Inc. (XAIR) Q3 2023 Earnings Call Transcript

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -2.38% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Beyond Air, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates

U.S. commercial launch continues for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023

Dr. Choy brings more than 20+ years of pharmaceutical and biotechnology operating experience to Beyond Cancer Dr. Choy brings more than 20+ years of pharmaceutical and biotechnology operating experience to Beyond Cancer

Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer

Dr. Dirbas, Associate Professor of Surgery at the Stanford School of Medicine will chair the Scientific Advisory Board (SAB)

Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D.

Call scheduled for Thursday, February 9th at 4:30 pm Eastern Time Call scheduled for Thursday, February 9th at 4:30 pm Eastern Time

Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Data describe a potent systemic immune response resulting in a significant reduction in challenge tumors and improvement in survival for UNO treated mice Data describe a potent systemic immune response resulting in a significant reduction in challenge tumors and improvement in survival for UNO treated mice

Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

GARDEN CITY, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and CEO of Beyond Air, will be presenting a corporate overview and participating in 1x1 meetings at the Piper 34th Annual Healthcare Conference being held November 29 – December 1, 2022 in New York, NY.

Beyond Air® To Participate in Piper's 34th Annual Healthcare Conference

Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2023 Results Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppenheimer & Co. Inc. Matthew Kaplan - Ladenburg Thalmann Greg Fraser - Truist Securities Operator Good afternoon. And welcome, everyone, to the Beyond Air Second Quarter 2023 earnings call.

Beyond Air, Inc. (XAIR) Q2 2023 Results - Earnings Call Transcript

Commercial launch underway for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023

-- Duration of oxygen support was significantly shorter for subjects treated with inhaled NO

News for Beyond Air Inc Stock (XAIR)